An estimated 37 million Americans have chronic kidney disease (CKD), and roughly 15 percent of CKD patients are believed to have anemia, with the prevalence increasing as the severity of CKD worsens. Anemia in CKD is associated with increased risk of CKD progression, poor cardiovascular (CV) outcomes, decreased health-related quality of life (HRQOL), and increased use of healthcare resources. Suboptimal management of anemia in CKD patients is common, and a novel agent in advanced development is poised to expand the armamentarium available to nephrology clinicians treating CKD patients with anemia. To help these clinicians manage their CKD patients’ anemia, Rockpointe and USF Health offer a free CME/CNE-certified, ABIM MOC/MIPS-eligible virtual webinar, available on two remaining dates.
Erythropoiesis-stimulating agents have been the standard of care for treating anemia in CKD but are associated with CV safety concerns; other therapies include red blood cell transfusions and iron administration, but each has potential severe adverse events (AE). Despite the expense and risk of AEs in treating anemia in CKD patients, studies have shown better HRQOL in patients without anemia and have demonstrated an economic advantage to raising patient hemoglobin (Hgb) levels. Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are promising novel agents in development for treating CKD-associated anemia. These oral agents increase endogenous erythropoietin production, improve iron absorption and mobilization, and decrease hepcidin production in the liver.
Lowering the Burden of Anemia in CKD: Looking to the Future with HIF-PHI’s is a is a continuing medical education (CME) program designed to familiarize nephrology clinicians with the etiology of anemia in CKD, the effects on health outcomes, quality of life, and function, advantages and limitations of current management strategies and the economic advantages of their use, and the efficacy and safety data for HIF-PHIs in late-stage development for the management of CKD-related anemia. Additional presentations on the program agenda —include reimbursement renal care changes with Robert Blazer, Director Government Affairs at the Renal Physicians Association and patient resources from the American Kidney fund are not mandatory for participant completion to receive credit. Participants will receive access to the post-test and evaluation after completing the first hour of content and will not receive credit for the additional presentations.
Webinar dates and times
Tuesday, October 25, 2022
7:00 – 9:00 PM ET (6:00 – 8:00 PM CT/ 4:00 – 6:00 PM PT)
Wednesday, November 30, 2022
3:00 – 5:00 PM ET (2:00 – 4:00 PM CT/ 12:00 – 2:00 PM PT)
At the program’s conclusion, participants should be able to:
- Summarize the etiology of anemia in chronic kidney disease.
- Describe the negative effects of anemia on health outcomes, quality of life, and functioning for patients with chronic kidney disease.
- Evaluate the advantages and limitations of current management strategies for anemia in chronic kidney disease.
- Assess the mechanism of action and efficacy and safety data for agents in late-stage development for the management of anemia of chronic kidney disease.
This program is CME/CNE-certified and ABIM MOC/MIPS-eligible and qualifies the participant for 1 hour of credit. There is no fee for this activity, which is supported by an educational grant from GlaxoSmithKline and is jointly provided by Rockpointe/CCO and USF Health in collaboration with the American Kidney Fund. Full accreditation information will be provided to participants prior to starting the course.
Through effective accredited continuing medical education, Rockpointe, a leader in educational programming with more than 26 years of experience and a division of Clinical Education Alliance (CEA), strives to improve and advance the quality of patient care. Its educational programs have been at the forefront of new issues in healthcare, including implementing MIPS, combatting the nation’s opioid and COVID-19 crises, recognizing issues with vaping, and utilizing technical advances in care. Sign up for CCO/Rockpointe’s CME course catalog and view a list of current educational opportunities, including on-demand webcourse offerings and live webinars, at www.rockpointe.com and www.clinicaloptions.com
As part of its commitment to quality, CCO/Rockpointe works to inform the continuing-education community of significant quality-improvement issues through news and analysis on Policy & Medicine, which offers a daily look at legal, regulatory, and compliance issues affecting the pharmaceutical and device industry. Rockpointe also publishes Policy & Medicine Compliance Update, a monthly publication that provides a concise update on compliance issues facing the life science industry and goes in-depth into important cases, laws, and regulations in straightforward articles. At CCO/Rockpointe, education equals quality.
To register for Lowering the Burden of Anemia in CKD, click here.